IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Lymphatic Diseases
Fudan Universitymonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Lymphatic Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bendamustine UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Zofran UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | B |
Ibrutinib Oncternal Therapeutics, Inc | Phase 3 | B |
Cyclophosphamide UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
View all 18 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →